1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one
C40H29N3O — CID 154006100
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one
1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one (PubChem CID 154006100) has the molecular formula C40H29N3O and a molecular weight of 567.69 g/mol. Its IUPAC name is 1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one.
Molecular Properties
| Compound Name | 1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one |
|---|---|
| PubChem CID | 154006100 |
| Molecular Formula | C40H29N3O |
| Molecular Weight | 567.69 g/mol |
| Exact Mass | 567.23 |
| IUPAC Name | 1-quinolin-3-yl-3-[2-(1-tritylimidazol-4-yl)phenyl]prop-2-en-1-one |
| SMILES | O=C(C=Cc1ccccc1-c1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1)c1cnc2ccccc2c1 |
| InChI | InChI=1S/C40H29N3O/c44-39(32-26-31-15-11-13-23-37(31)41-27-32)25-24-30-14-10-12-22-36(30)38-28-43(29-42-38)40(33-16-4-1-5-17-33,34-18-6-2-7-19-34)35-20-8-3-9-21-35/h1-29H |
| InChIKey | XXZKBPLLAARAKQ-UHFFFAOYSA-N |
| XLogP | 8.83 |
| TPSA | 47.78 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 44 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 567.69 |
| LogP ≤ 5 | 8.83 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'}, {'alert_name': 'triphenyl_methyl-silyl', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 154006100 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.